Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk (NYSE: NVO)- ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

London's Financial Times highlights improved weight loss from taking more Ozempic. Eli Lilly's Mounjaro still seems more effective. Novo Nordisk stock is responding positively to the news, up 2.1% ...

Novo Nordisk A/S plans to seek US regulatory approval for a high-dose version of its blockbuster weight-loss shot Wegovy, another effort to counter Eli Lilly & Co. in the booming obesity market.

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Novo Nordisk has recently encountered headwinds in its core therapeutic area. The company has implemented changes that could pay off in the long run. Novo Nordisk's shares look reasonably valued. Two ...

Novo Nordisk’s Wegovy weight-loss drug helps patients stop thinking about food, according to a new study. According to results of the study, which were presented at a medical conference in Austria, ...

Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get the shot version, fueling new optimism that oral GLP-1 drugs could expand an ...

Novo Nordisk’s NOVO.B0.28%increase; green up pointing triangle experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage ...

Despite the difficulties Novo Nordisk's GLP-1 franchise has encountered due to Eli Lilly and manufacturers of compounded versions of semaglutide, demand for Wegovy remains strong. So, its sales ...

VIENNA, Sept 18 (Reuters) - Novo Nordisk might be down but it's not out of the weight-loss drug race. The Danish maker of blockbuster drug Wegovy has had a miserable year with stalling sales growth, ...